Cost-Effectiveness Analysis of CAB-LA for PrEP in the United States

This content is paid for and developed by ViiV Healthcare.

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 conference on May 10, 2022, in Washington, DC, Ashley E. Davis, PhD, director of health economics at RTI Health Solutions, presented the findings from a cost-effectiveness analysis of cabotegravir long-acting for PrEP in the United States, where it was 1 of 3 winners from more than 1600 submissions for “Best General Podium Research Presentation”. RTI Health Solutions received funding for this study from ViiV Healthcare. ViiV Healthcare sponsored the development of the model. This article summarizes the presentation highlights and was not peer reviewed.

Davis AE, Brogan AJ, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness analysis of CAB-LA for PrEP in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022; Washington, DC.

INTENDED FOR DISTRIBUTION ONLY TO PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES FOR HEALTHCARE ECONOMIC ANALYSIS PURSUANT TO SECTION 114 OF THE FOOD AND DRUG MODERNIZATION ACT TO FACILITATE DRUG SELECTION, ON A POPULATION BASIS, FOR COVERAGE OR REIMBURSEMENT.